anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) with low skeletal muscle mass and severe airway obstruction have higher mortality risks. However, the relationship between dynamic/static lung function (LF) and thoracic skeletal muscle measurements (SMM) remains unclear. This study explored patient characteristics (weight, BMI, exacerbations, dynamic/static LF, sex differences in LF and SMM, and the link between LF and SMM changes.
METHODS: A retrospective analysis of a 12-month prospective follow-up study patients with stable COPD undergoing standardized treatment, covering mild to severe stages, was conducted. The baseline and follow-up assessments included computed tomography and body plethysmography.
RESULTS: This study included 35 patients (17 females and 18 males). This study revealed that females had more stable LF but tended to have greater declines in SMM areas and indices than males (-5.4% vs. -1.9%, respectively), despite the fact that females were younger and had higher LF and less exacerbation than males. A multivariate linear regression showed a negative association between the inspiratory capacity/total lung capacity ratio (IC/TLC) and muscle fat area.
CONCLUSIONS: The findings suggest distinct LF and BC progression patterns between male and female patients with COPD. A low IC/TLC ratio may predict increased muscle fat. Further studies are necessary to understand these relationships better.
PROBLEM TO BE SOLVED: To easily obtain the subject composition advantageous in terms of cost, and useful as a two-way cake having incomparable cosmetic characteristics and high sustainability thereof by including a particle phase containing a specified proportion of a hydrophilic powdery compound. SOLUTION: This composition is obtained by including pref. 77-99 wt.% of a particle phase containing 20-35 wt.% of a hydrophilic powdery compound (pref. mica of natural origin such as muscovite, mica of synthetic origin, bismuth oxychloride, or the like); wherein the powdery compound is preferably selected from fillers (pref. mica, talc or the like), pigments (pref. titanium dioxide, zinc oxide, or the like) and/or pearly agents and/or mixtures thereof; and it is preferable that this composition is incorporated with 1-85 wt.% of talc and 0.1-5 wt.% of a pigment.
Pulmonary vascular remodeling and inflammation play an important role in the hypoxic-induced lung diseases. Our previous investigations showed that peptide from yak milk residues could alleviate inflammation. In this study, our results suggest that peptide (LV) from yak milk residues peptide had protective effect of lung in the animal models of hypoxic-induced lung injury. LV Gavage could improve pulmonary vascular remodeling in the lung tissues of hypoxic mice. A comprehensive analysis of metabolomics and transcriptomics revealed that 5-KETE, 8,9-EET, and 6-keto-prostaglandin F1a might be potential targets to prevent lung injury in the hypoxic mice. These metabolites can be regulated by MAPK/VEGF and inflammatory pathways. Our data indicated that LV treatment could inhibit apoptosis and inflammation via Nrf2/NF-κB/MAPK/PHD-2 pathway and protected hypoxic-induced lung epithelial cells injury. Taken together, our results suggest that LV provides a novel therapeutic clue for the prevention of hypoxia-induced lung injury and inflammation-related lung diseases.
BACKGROUND: Dietary sodium restriction remains a guidelines-approved lifestyle recommendation for chronic heart failure (CHF) patients. However, its efficacy in clinical outcome improvement is dubious.
OBJECTIVE: The study evaluated whether dietary sodium restriction in CHF reduces clinical events.
METHODS: We performed a systematic review of the following databases: Academic Search Ultimate, ERIC, Health Source Nursing/Academic Edition, MEDLINE, Embase, Clinicaltrials.gov and Cochrane Library (trials) to find studies analysing the impact of sodium restriction in the adult CHF population. Both observational and interventional studies were included. Exclusion criteria included i.e.: sodium consumption assessment based only on natriuresis, in-hospital interventions or mixed interventions-e.g. sodium and fluid restriction in one arm only. The review was conducted following PRISMA guidelines. Meta-analysis was performed for the endpoints reported in at least 3 papers. Analyses were conducted in Review Manager (RevMan) Version 5.4.1.
RESULTS: Initially, we screened 9175 articles. Backward snowballing revealed 1050 additional articles. Eventually, 9 papers were evaluated in the meta-analysis. All-cause mortality, HF-related hospitalizations and the composite of mortality and hospitalisation were reported in 8, 6 and 3 articles, respectively. Sodium restriction was associated with a higher risk of the composite endpoint (OR 4.12 [95% CI 1.23-13.82]) and did not significantly affect the all-cause mortality (OR 1.38 [95% CI 0.76-2.49]) or HF hospitalisation (OR 1.63 [95% CI 0.69-3.88]).
CONCLUSIONS: In a meta-analysis, sodium restriction in CHF patients worsened the prognosis in terms of a composite of mortality and hospitalizations and did not influence all-cause mortality and HF hospitalisation rate.
The hepatitis B virus (HBV) chronic infection goes through different phases, i.e., immune tolerant (IT), immune clearance (IC), and inactive carrier (IN) resulting from the interplay of viral replication and immune response. Although the adaptive immune response is central to viral control, roles of the innate immune cells are less prominent. We explored monocyte transcriptome in these different phases of HBV infection to understand the nature of its involvement and identify unique differentially expressed genes (DEGs) in each phase. CD14+ peripheral blood monocytes were isolated from patients in the IT, IC, and IN phases and from healthy subjects and their RNA was sequenced. The significant DEGs were studied through gene annotation databases to understand differentially modulated pathways. The DEGs were further validated by qRT-PCR to identify genes that were uniquely expressed in each phase. It was found that TNFRSF12A was upregulated in all the HBV samples. The IN phase had six uniquely upregulated genes, i.e., PI3, EMP1, STX1A, RRAD, SPINK1, and SNORD3B-2. E2F7 was most consistently downregulated in the IT phase, and in the IC phase, IL23A and PI3 were specifically downregulated. Cut-off values were generated by ROC curve analysis to differentiate between the groups based on their expression levels. The monocyte functions are majorly suppressed in the IT and IC phases and are, however, somewhat metabolically active in the IN phase.
FIELD: cosmetics, particularly, creams for face and skin. SUBSTANCE: cream contains the following components in preset ratio: olive oil, lanolin, glycerine, emulsion waxes, methyl ether of n-oxybenzoic acid, propyl ether of n-oxybenzoic acid, superoxidedismutase, carnosine, tocopherolacetate, ascorbilpalmitate, butylhydroxytoluene, lecithin, oil of wheat germs, diethyleneglycol stearate, isopropylmyristate, high-molecular C 16 -C 18  hydrogenated alcohols, flavor and water. The cream ensures intensive moistening action, correction and prophylaxis of withering skin, suppresses process of senescence, and activates mechanism of skin regeneration. The proposed cream is recommended as a curative-and-prophylactic agent for complex therapy of nonspecific colpitis and vaginose, pustular and herpetic affection of skin and mucous. EFFECT: higher efficiency. 1 tbl, 3 ex
De Quervain's tenosynovitis is the most common complication after total trapeziometacarpal joint replacement. Etiology is unclear. Implantation of a ball-in-socket implant changes the biomechanics of the normal trapeziometacarpal saddle joint and increases its range of motion. The present study demonstrates that this procedure also significantly increases excursion of the abductor pollicis longus and extensor pollicis brevis tendons during thumb flexion-extension, and not during thumb abduction-adduction. Increased tendon gliding under the retinaculum of the first extensor tendon compartment could predispose to the development frictional tenosynovitis and play a role in the development of de Quervain's syndrome after total trapeziometacarpal joint replacement. LEVEL OF EVIDENCE: Not applicable (laboratory study).
Participants of the intervention group will receive an intervention manual and videos. The duration of the intervention will be six weeks. Participants will be asked for a minimum time investment of 60 min per week. The intervention will be delivered via WeChat video call. The intervention will be conducted following the intervention manual to ensure consistency of intervention content that delivered.
Each participant receives their treatment of Quercetin LipoMicel at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 500 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
The invention belongs to the technical field of biology, and particularly relates to a liver-targeted small nucleic acid drug sustained-release delivery system and application thereof. The technical problem to be solved by the invention is that the in vivo uptake rate and stability of the GalNAc-small nucleic acid medicament are not good. The technical means for solving the technical problems is to provide a liver targeting small nucleic acid drug sustained-release delivery system. The present invention uses the cholesterol-modified polypeptide DP7-C to efficiently deliver GalNAc-micronucleic acid drugs to liver cells. The DP 7-C/GalNAc-small nucleic acid drug compound is dispersed in the hydrogel to form a new delivery system, so that the stability of the GalNAc-small nucleic acid drug can be effectively kept, the long-acting slow release effect can be achieved, and the in vivo application effect is good. The technical scheme of the invention has the advantages of convenient preparation, low toxicity, safety and short preparation period, and has higher transfection efficiency, lower cytotoxicity, better long-acting slow release effect and good application prospect compared with the existing delivery system.
Adults, 18 years and older will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect your physical, emotional, or mental well-being (BRIEF-A and ABCL questionnaires). The adult will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality. Additionally, the adult will need to take their blood pressure 3 times per day for 14 days and record measurements.
A remotely-interfaceable electrocardiography patch is provided. A flexible backing is formed from an elongated strip of material. A pair of electrocardiographic electrodes are exposed on a contact surface of the flexible backing for capturing electrocardiographic signals. A non-conductive receptacle is adhered to an outward-facing surface of the flexible backing and includes a plurality of electrical pads. A flexible circuit has a pair of circuit traces electrically coupled to the pair of electrocardiographic electrodes and a pair of the electrical pads. A wireless transceiver communicates samples of the electrocardiographic signals.
Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
1,177,796. Hair spray lacquer. NATIONAL STARCH & CHEMICAL CORP. 15 March, 1967 [18 March, 1966], No. 12207/67. Heading A5B. [Also in Divisions C2, C3 and C4] An aerosol composition for use as a hair spray lacquer comprises an organic solvent solution of an ultra-violet absorbing film-forming copolymer in admixture with a propellant therefor. The copolymer may be a copolymer of an ethylenically unsaturated derivative of phenyl salicylate, benzophenone, benzotriazole or a phenol (wherein the ethylenic unsaturation is ortho to the hydroxyl) with a vinyl ester; alkyl or hydroxyalkyl acrylate or methacrylate; acrylic, methacrylic, itaconic or crotonic acid; or an alkyl half-ester of maleic or fumaric acid. Co-polymers with vinyl esters may be partially hydrolysed. The preparation of many such copolymers having up to 5 monomers is described. The propellant may be trichlorofluoromethane, dichlorodifluoromethane, isobutane or propane or mixtures thereof. Optional ingredients include glycols, phthalate esters and glycerine plasticisers; silicones, lanolin, protein hydrolysates, ethylene oxide adducts and polyoxyethylene cholesterol.
The invention discloses a compound Longxuejie preparation and a preparation method thereof. The compound Longxuejie preparation is mainly prepared by the bulk pharmaceutical chemicals: Longxuejie, pseudo-ginseng and borneol in parts by weight. The preparation method specifically comprises the steps of: crushing the Longxuejie and the pseudo-ginseng respectively and extracting the effective active ingredients; then adding a proper amount of borneol, drying, mixing adequately, and crushing to obtain the preparation. Different auxiliary materials are added into the preparation to prepare common orally taken pharmaceutical dosage forms. The toxicologic and pharmacologic test results of the preparation show that the preparation is free from toxic side effects, can promotes blood circulation and removes blood stasis effectively and can be used for treating diseases such as coronary heart disease, angina, myocardial infarction, blood stasis and the like with obvious curative effect. The compound Longxuejie is a pure traditional Chinese medicine compound preparation which is safe, high in content of active ingredients, low in dosage and appropriate in cost and has good application prospect.
Previous studies have identified strategies for the large-scale identification of acute HIV infections. One system using such strategies has already been implemented in North Carolina, and this system will be used in this study run by the Center of HIV/AIDS Vaccine Immunology (CHAVI). This study will collect data on the mechanism of HIV transmission and the genetic, biologic, antigenic, and structural characteristics of the virus. The study will enroll HIV infected people with acute HIV infection and their sexual partners, people with established HIV infection, and HIV uninfected people.

This study will last 96 weeks. Group 1 participants will be people with acute HIV infection. These participants will have 15 study visits; some visits will include a physical exam and medical history. Group 1 will also be asked to complete a sexual behavioral assessment at study entry and every 12 weeks thereafter. Group 2 participants will be people with established HIV infection. Group 3 participants will be HIV uninfected people. Groups 2 and 3 will have 10 study visits; some visits will include a physical exam and medical history. Groups 2 and 3 will also be asked to complete a sexual behavioral assessment at study entry, every 12 weeks until Week 72, and Week 96. Group 3 will undergo HIV testing at each visit and will receive pre- and post-test counseling.

At each visit, participants will undergo HIV safe sex counseling and will update their locator information. Blood, genital secretion, and breast milk collection will also occur at each visit.
Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
HUMIRA® (adalimumab) is supplied as a preservative-free, sterile, clear and colorless solution for subcutaneous administration. The following packaging configurations are available. 

  * HUMIRA Pen Carton - 40 mg/0.4 mL   
HUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is 83457-554-02   

  * HUMIRA Pen Carton – 80 mg/0.8 mL   
HUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 80 mg/0.8 mL of HUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is 83457-124-02.  

  * Prefilled Syringe Carton - 40 mg/0.4 mL   
HUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 40 mg/0.4 mL of HUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is 83457-243-02.   

  * Prefilled Syringe Carton - 20 mg/0.2 mL   
HUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 20 mg/0.2 mL of HUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is 83457-616-02.   

  * Prefilled Syringe Carton - 10 mg/0.1 mL   
HUMIRA is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, ½ inch needle, providing 10 mg/0.1 mL of HUMIRA. The black needle cover is not made with natural rubber latex. The NDC number is 83457-817-02. 



Storage and Stability

Do not use beyond the expiration date on the container. HUMIRA must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed. 

Store in original carton until time of administration to protect from light. 

If needed, for example when traveling, HUMIRA may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 14 days, with protection from light. HUMIRA should be discarded if not used within the 14-day period. Record the date when HUMIRA is first removed from the refrigerator in the spaces provided on the carton and dose tray. 

Do not store HUMIRA in extreme heat or cold.
BACKGROUND: Identifying risk factors associated with the Motoric Cognitive Risk (MCR) syndrome (a pre-dementia syndrome) can assist in developing risk reduction strategies and interventions to delay progression to dementia. Tailored interventions require comparisons of high- and middle-income countries to determine if the same or different risk factors should be targeted. We examined risk factors associated with MCR in seven Health and Retirement Studies with harmonized measures.
METHODS: Data from adults aged ≥65 years (n = 20,036, mean age 71.2(SD 6.2)-80.1(SD 4.1)) from the U.S. Health and Retirement Study, English Longitudinal Study of Aging, Survey of Health, Aging and Retirement in Europe, China Health and Retirement Longitudinal Study, Harmonized Diagnostic Assessment of Dementia for Longitudinal Aging Study in India, Mexican Health and Aging Study, and Brazilian Longitudinal Study of Aging was included. MCR was defined as the presence of cognitive complaints and slow gait (no mobility disability and dementia). Associations of demographic [education], medical [hypertension, diabetes, heart disease, obesity, stroke, Parkinson's, falls], psychological [depressive symptoms, psychiatric problems], sensorimotor [grip strength, hearing], and behavioral factors [smoking, sedentariness, sleep], with prevalent MCR were examined using age- and sex-adjusted logistic regression models. A meta-analysis was performed to compare risk factors for MCR in high- versus middle-income countries.
RESULTS: Except for depressive symptoms and weak grip strength, different risk factor clusters were associated with individual studies. Poor sleep, hearing, weak grip, and multiple falls emerged as novel associations with MCR. When grouped by income, some risk factors (i.e., education) were associated with MCR in high- and middle-income countries. Others (i.e., obesity) were specific to high-income countries.
CONCLUSIONS: This cross-sectional, cross-national study identified new, shared, and specific risk factors associated with MCR in high- and middle-income countries, providing insights to develop public health approaches and interventions to forestall the onset of dementia in those with MCR.
PURPOSE: Speech-language pathology (SLP) is considered an essential intervention due to the high prevalence of dysphagia and dysarthria in paediatric neuromuscular disorders (pNMD). Evidence-based guidelines for SLP in pNMD are missing and children could be deprived the best of care. This study aimed to achieve consensus and present best practice recommendations on SLP intervention in pNMD.
METHOD: A modified Delphi technique was used with a panel of experienced Dutch speech-language pathologists. In two online survey rounds and a face-to-face consensus meeting, the SLP experts proposed intervention items for cases of four types of pNMD (congenital myopathy, Duchenne muscular dystrophy, myotonic dystrophy type 1, and spinal muscular atrophy type 2), covering symptoms of dysphagia, dysarthria, drooling, and oral hygiene problems. They rated the level of agreement.
RESULT: Intervention items that achieved consensus were incorporated into best practice recommendations. These recommendations cover six core intervention components (wait and see, explanation and advice, training and treatment, aids and adjustments, referral to other disciplines, and monitoring) suitable for the described symptoms.
CONCLUSION: Insight into treatment options is essential to facilitate speech-language pathologists in clinical decision-making. The current study led to best practice recommendations for speech-language pathologists working within the field of pNMD.
PROBLEM TO BE SOLVED: To obtain a powdery polymer/powdery material mixture by mixing a specific powdery polymer with a powdery material, and further to obtain a cosmetic excellent in touch by using the mixture. SOLUTION: A powdery polymer having an average primary particle diameter of 0.1-20μm is ground in a volatile solvent, and the obtained ground solution is mixed with a powdery material or further an oiling agent. The volatile solvent is removed from the mixture to obtain the powdery polymer.powdery material mixture, which is added in an amount of 1-100 pts.wt. per 100 pts.wt. of a cosmetic to obtain the cosmetic. A silicone resin, teflon, a nylon, etc., is preferable used as the polymer, because an ability for controlling the touch of the cosmetic is large. The volatile solvent includes a cyclic silicone, methylene dichloride, and fluorocarbons. The powdery material includes the red color No. 104, and nylon powder. The powdery polymer and the powdery material are used in a weight ratio of 100:1 to 1:100. The oiling agent includes stearyl alcohol and glycerol.  The powdery polymer and the powdery material are used in a total amount weight ratio of 0.1:100 to 20:100.
NEW MATERIAL:The alpha-substituted aminothiazole derivative of formula I [R1 and R2 are lower alkyl, (substituted)benzyl or (substituted)phenyl (provided that both R1 and R2 are not substituted phenyl at the same time); R3 is H or acyl; n is integer of 0-4] and its acid addition salt. EXAMPLE:4,5-Dimethyl-2-(3-morpholinopropyl)aminothiazole. USE:A drug having anti-inflammatory analgesic action. It has low side effect and chronic inflammation suppressing action as well as acute inflammation suppression action and analgesic action. PREPARATION:The compound of formula I can be produced by reacting a compound of formula II with a compound of formula III in an organic solvent (e.g. methanol or dimethylformamide).